FDA to discuss easing restrictions on peptides despite safety concerns

Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy

Advisers to the Food and Drug Administration (FDA) will soon hold a meeting about whether to ease restrictions on access to some research peptides, a group of drugs with a zealous following and thin evidence to support them.

If restrictions are eased, US compounding pharmacies would be able to produce and fill prescriptions for Americans – a change that would effectively legalize a thriving gray market.